-
Qianhong pharmaceutical enoxaparin sodium product is about to be approved for production
Time of Update: 2015-05-19
According to the information on CFDA's website on May 19, Qianhong Pharmaceutical (002550 SZ) changed its application status of enoxaparin sodium product to "approved - to be certified" Previously, th
-
Taipei Medical University has developed a new anticancer small molecule drug mpt0e028
Time of Update: 2015-05-19
The team of Taipei Medical University has developed new cancer drugs to bring good news to cancer patients The team of Changgeng University (provided by Beijing Medical University) developed a highly
-
Changzhou Yinsheng Pharmaceutical Co., Ltd., Sichuan University and Wuxi Wuxi Pharmaceutical Co., Ltd. jointly develop a new drug of anti drug resistant tuberculosis
Time of Update: 2015-05-18
On May 17, Changzhou Yinsheng Pharmaceutical Co., Ltd signed a tripartite agreement with Sichuan University and Shanghai yaomingkant new drug development Co., Ltd to jointly develop a new drug resista
-
Baiji Shenzhou, an innovative anti-tumor drug R & D company, obtained a financing of RMB 600 million
Time of Update: 2015-05-18
Baiji Shenzhou is an innovative anti-tumor company, mainly engaged in tumor targeting and tumor immunotherapy Today, the company has successfully secured 970m of financing Companies involved in the fi
-
CDE Drug Evaluation Weekly Report (2015.5.10-2015.5.16)
Time of Update: 2015-05-18
In the review this week (2015.5.10-2015.5.16), a total of 111 drugs (excluding supplementary application and review, calculated according to the acceptance number, the same below) entered the review p
-
Three key phase I clinical trials of risperidone sustained-release microsphere intramuscular injection preparation ly 03004 in the United States
Time of Update: 2015-05-18
On May 14, green leaf Pharmaceutical Group Co., Ltd announced that its self-developed muscle injection preparation of risperidone sustained release microspheres (ly 03004) for the treatment of schizop
-
Three first-class new drugs in Fujian are approved for market
Time of Update: 2015-05-17
On May 15, it was learned from the food and Drug Administration of Fujian Province that three first-class new drug varieties of three pharmaceutical enterprises in Fujian Province were approved by the
-
Wuhu Kangwei class 1 new gastritis vaccine is about to obtain production license
Time of Update: 2015-05-17
Wuhu Kangwei class 1 new drug "oral Recombinant Helicobacter pylori vaccine" of Yueyang Xingchang joint stock company is in the stage of production license examination This means that by the end of th
-
Vonolazan fumarate, a class 3.1 anti gastric acid drug of Huadong pharmaceutical, China and the United States, entered the Evaluation Center
Time of Update: 2015-05-15
Vonolazan fumarate, a class 3.1 anti gastric acid drug declared by Hangzhou Zhongmei Huadong Pharmaceutical Co., Ltd., entered the evaluation center on May 5, 2015 Tak-438 (VO noprazan fumarate) is a
-
Halometasone, the first new drug of Huabang pharmaceutical, will be approved soon
Time of Update: 2015-05-15
According to the website of the State Food and Drug Administration (CFDA) on May 15, the status of Halometasone, a new drug for external use of Huabang pharmaceutical, has changed to "under approval",
-
CDE drug review report in April 2015
Time of Update: 2015-05-14
Key points in April, the drug declaration volume reached the highest level since this year, Zhengda Tianqing declared for the first time in nearly four years that the chemical medicine 1.1 new drug Qi
-
A batch of "made in Xiamen" biomedical products sell well in the world
Time of Update: 2015-05-12
Biology and new medicine industry is one of the ten hundred billion industry chains (clusters) that our city strives to build Xiamen's biological and new pharmaceutical industry has many initiatives T
-
Fuhong Hanlin obtained the second clinical approval of monoclonal antibody drugs
Time of Update: 2015-05-06
On April 28, Fosun Pharmaceutical holding company Shanghai Fuhong Hanlin Biotechnology Co., Ltd (hereinafter referred to as "Fuhong Hanlin") formally received the second clinical approval document of
-
Application for registration of shutaishen new drug "mouse nerve growth factor for injection" has not been approved
Time of Update: 2015-05-06
Shutaishen (300204) announced in the evening of May 5 that on April 30, the company received the notice of approval opinions from the State Food and drug administration The new drug "rat nerve growth
-
Big data becomes "catalyst" for drug innovation
Time of Update: 2015-05-05
The 2015 China (Beijing) International Technology Transfer Conference is the most fashionable vocabulary at present Because of its ability to quickly obtain valuable information from various types of
-
CDE drug review weekly report (April 26, 2015 to May 2, 2015)
Time of Update: 2015-05-04
Introduction: 1 Zhengda Tianqing is the second one in China to declare its class 3.1 non-small cell lung cancer and small cell cancer treatment drug adrobicin; 2 Zhengda Tianqing is the second one in
-
It is not clear whether the change of application status of metoxadone tablet, a new drug of shutaishen, has been approved
Time of Update: 2015-05-04
According to the information on the website of CFDA on May 4, the processing status of shutaishen new drug methadone tablet was changed to "approved - to be certified", but it was not found that it ha
-
Heyuan biological a new drug "rice hematopoiesis" will be applied for clinical trials within this year
Time of Update: 2015-04-29
On April 27, Wuhan University National Science and Technology Park, in conjunction with Shenzhen investment banking circle, held a docking meeting on venture capital investment and financing in the "s
-
In 2014, Guangdong Province completed 22 class 1 new drug applications
Time of Update: 2015-04-29
On April 29, Guangdong food and Drug Administration held a regular press conference for the first quarter of 2015 At the meeting, it was revealed that Guangdong province accounted for a quarter of the
-
Qilu pharmaceutical imitates trelagriptin, a heavy-duty hypoglycemic drug once a week
Time of Update: 2015-04-29
Not long ago, the world's first weekly oral hypoglycemic drug, trilagliptin, was approved for marketing in Japan (under the trade name of zafatek), developed by Takeda pharmaceutical, known as the hea
